Sascha M Keij, Anne M Stiggelbout, Arwen H Pieterse
Patient readiness for shared decision making about treatment: Conceptualisation and development of the ReadySDM
Health expectations : an international journal of public participation in health care and health policy
worlds first oral nuclear export inhibitor selinexor increasingly used clinical applications malignant tumors however extensive exploration selinexors adverse events ades necessitating realword assessment clinical medication safety faers data july 2019june 2023 searched selinexor ade reports across indications use system organ class soc preferred terms pt medical dictionary regulatory activities meddra describe categorize statistic ades disproportionality analysis employed calculation reporting odds ratio ror proportional reporting ratio prr based total 4392 selinexor related ade reports primary suspect ps 2595 instances severe outcomes predominant ades included gastrointestinal disorders myelosuppression symptoms various nonspecific manifestations 124 signals associated selinexor ade detected 10 top 15 signals included instructions study provides realworld evidence regarding drug safety selinexor crucial clinicians safeguard patients health